Home cancer injections: a new hope for myeloma patients?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * ≥ 18 years of age at the time of signing the informed consent form. * Relapsed MM according to the IMWG criteria. * Measurable disease defined as: M-protein quantities ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) and/or Serum free light chain (FLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda (κ/λ) ratio in patients without measurable disease in the serum or urine. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0, 1 or 2. * Previously exposed to at least two of the following; one proteasome inhibitor, one IMID, or one anti CD-38 antibody. * Documented disease progression during or after last anti-myeloma regimen. * Possibility of being observed by a capable caregiver during self-administration. * ANC ≥1.0 x 109/L (G-CSF allowed). * Platelets ≥25 x 109/L. * Female patients of childbearing potential must have a negative serum pregnancy test at screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment. Exclusion Criteria: * Any significant medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from participating in the study. * Prior history of ICANS. * Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years with the exception of the following non-invasive malignancies: * Basal cell carcinoma of the skin * Squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Carcinoma in situ of the breast * Incidental histologic finding of prostate cancer (T1a or T1b using the TNM \[tumor, nodes and metastasis\] clinical staging system) or prostate cancer that is curative * Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or clinically significant Amyloidosis. * Female who is pregnant, breastfeeding or who intends to become pregnant during the participation in the study. * Positivity for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C. * Resident on an unbridged island. * Not being able to register PRO-data electronically.